Search
Now showing items 1-4 of 4
Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry.
(J Am Heart Assoc, 2013-07-18)
BACKGROUND: The prevalence of atrial fibrillation (AF) continues to increase; however,
there are limited data describing the division of care among practitioners in the
community and whether care differs depending on provider ...
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
(J Am Heart Assoc, 2013-11-25)
BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis
in atrial fibrillation. Adoption patterns of this new agent in community practice
are unknown. METHODS AND RESULTS: We studied patterns ...
How Reliable are Patient-Reported Rehospitalizations? Implications for the Design of Future Practical Clinical Studies.
(J Am Heart Assoc, 2016-01-25)
BACKGROUND: Longitudinal clinical investigations often rely on patient reports to
screen for postdischarge adverse outcomes events, yet few studies have examined the
accuracy of such patient reports. METHODS AND RESULTS: ...
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
(Eur Heart J, 2015-12-07)
BACKGROUND: Therapeutic decisions in atrial fibrillation (AF) are often influenced
by assessment of bleeding risk. However, existing bleeding risk scores have limitations.
OBJECTIVES: We sought to develop and validate a ...